Dendritic cell-based vaccines: From mouse models to clinical cancer immunotherapy

Critical Reviews in Oncogenesis

Volumn 11, Issue 1, 2000, Pages 1-17

  Schreurs, Marco W J ^b   Eggert, Andreas A O ^b   Punt, Cornelis J A ^a   Figdor, Carl G ^b   Adema, Gosse J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Cancer; Dendritic cells; Immunotherapy; Tumor; Vaccination

Indexed keywords

CANCER VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELLULAR DISTRIBUTION; CLINICAL IMMUNOLOGY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION;

EID: 0033993529     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevoncog.v11.i1.10     Document Type: Review

References (126)

1. Adema, G. J., F. Hartgers, R. Verstraten, E. De Vries, G. Marland, S. Menon, J. Foster, Y. Xu, P. Nooyen, T. Mcclanahan, K. B. Bacon, and C. G. Figdor: A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature, 387:713-717 (1997).
2. Albert, M. L., B. Sauter, and N. Bhardwaj: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 392:86-89 (1998).
3. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis: Phenotypic analysis of antigen-specific T lymphocytes. Science, 274:94-96 (1996).
4. Anjuere, F., P. Martin, I. Ferrero, M. L. Fraga, G. M. del Hoyo, N. Wright, and C. Ardavin: Definition of dendritic cell subpopulations present in the spleen, Peyer's patches, lymph nodes, and skin of the mouse. Blood, 93:590-598 (1999).
5. Ardavin, C., L. Wu, C. L. Li, and K. Shortman: Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature, 362:761-763 (1993).
6. Ashley, D. M., B. Faiola, S. Nair, L. P. Hale, D. D. Bigner, and E. Gilboa: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med., 186:1177-1182 (1997).
7. Austyn, J. M.: Antigen uptake and presentation by dendritic leukocytes. Semin. Immunol., 4:227-236 (1992).
8. Bakker, A. B. H., G. Marland, A. J. De Boer, R. J. Huijbens, E. H. Danen, G. J. Adema, and C. G. Figdor: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55:5330-5334 (1995).
9. Banchereau, J. and R. M. Steinman: Dendritic cells and the control of immunity. Nature, 392:245-252 (1998).
10. Bender, A., M. Sapp, G. Schuler, R. M. Steinman, and N. Bhardwaj: Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Meth., 196:121-135 (1996).
11. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184:465-472 (1996).
12. Boon, T., P. G. Coulie, and B. van den Eynde: Tumor antigens recognized by T cells. Immunol. Today, 18:267-268 (1997).
13. Brocker, E. B., G. Zwadlo, L. Suter, M. Brune, and C. Sorg: Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol. Immunother., 25:81-86 (1987).
14. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan: Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol., 158:3270-3276 (1997).
15. Carbone, F. R., C. Kurts, S. R. Bennett, J. F. Miller, and W. R. Heath: Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today, 19:368-373 (1998).
16. Caux, C., C. Dezutter Dambuyant, D. Schmitt, and J. Banchereau: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature, 360:258-261 (1992).
17. Caux, C., B. Vanbervliet, C. Massacrier, C. Dezutter Dambuyant, B. Desaintvis, C. Jacquet, K. Yoneda, S. Imamura, D. Schmitt, and J. Banchereau: CD34(+) hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J. Exp. Med., 184:695-706 (1996).
18. Cella, M., D. Scheidegger, K. Palmerlehmann, P. Lane, A. Lanzavecchia, and G. Alber: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184:747-752 (1996).
19. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature, 388: 782-787 (1997).
20. Cella, M., M. Salio, Y. Sakakibara, H. Langen, I. Julkunen, and A. Lanzavecchia: Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med., 189: 821-829 (1999).
21. Celluzzi, C. M. and L. D. Falo, Jr.: Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol., 160: 3081-3085 (1998).
22. Chen, L.: Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. Curr. Opin. Immunol., 11: 219-222 (1999).
23. Czerkinsky, C. C., L. A. Nilsson, H. Nygren, O. Ouchterlony, and A. A. Tarkowski: Solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Meth., 65: 109-121 (1983).
24. + T-cell help to elicit protective and therapeutic antitumor immunity. J. Immunol., 162: 144-151 (1999).
25. Dhodapkar, M. V., R. M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S. M. Donahoe, P. R. Dunbar, V. Cerundolo, D. F. Nixon, and N. Bhardwaj: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest., 104: 173-180 (1999).
26. Eggert, A. A., M. W. Schreurs, O. C. Boerman, W. J. Oyen, A. J. de Boer, C. J. Punt, C. G. Figdor, and G. J. Adema: Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res., 59: 3340-3345 (1999).
27. Eljaafari, A., K. Duperrier, S. Mazet, C. Bardin, J. Bernaud, B. Durand, L. Gebuhrer, H. Betuel, and D. Rigal: Generation of stable monocyte-derived dendritic cells in the presence of high concentrations of homologous or autologous serum: influence of extra-cellular pH. Hum. Immunol., 59: 625-634 (1998).
28. Enk, A. H., H. Jonuleit, J. Saloga, and J. Knop: Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer, 73: 309-316 (1997).
29. Esche, C., V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M. R. Shurin: FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res., 58: 380-383 (1998).
30. Facchetti, F., C. de Wolf-Peeters, H. de Greef, and V. J. Desmet: Langerhans cells in various benign and malignant pigment-cell lesions of the skin. Arch. Dermatol. Res., 276: 283-287 (1984).
31. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate antitumor immune responses in vivo. Nat. Med., 5: 405-411 (1999).
32. Fields, R. C., K. Shimizu, and J. J. Mulle: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and m vivo. Proc. Natl. Acad. Sci. U.S.A., 95: 9482-9487 (1998).
33. Finke, J., S. Ferrone, A. Frey, A. Mufson, and A. Ochoa: Where have all the T cells gone? Mechanisms of immune evasion by rumors. Immunol. Today, 20: 158-160 (1999).
34. Freudenthal, P. S. and R. M. Steinman: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc. Natl. Acad. Sci. U.S.A., 87: 7698-7702 (1990).
35. Grabbe, S., S. Bruvers, R. L. Gallo, T. L. Knisely, R. Nazareno, and R. D. Granstein: Tumor antigen presentation by murine epidermal cells. J. Immunol., 146: 3656-3661 (1991).
36. Grabbe, S., S. Bruvers, A. M. Lindgren, J. Hosoi, K. C. Tan, and R. D. Granstein: Tumor antigen presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and ultraviolet radiation. J. Leukoc. Biol., 52: 209-217 (1992).
37. Granziero, L., S. Krajewski, P. Farness, L. Yuan, M. K. Courtney, M. R. Jackson, P. A. Peterson, and A. Vitiello: Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur. J. Immunol., 29: 1127-1138 (1999).
38. Hart, D. N.: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 90: 3245-3287 (1997).
39. Hart, I. and C. Colaco: Immunotherapy. Fusion induces tumour rejection. Nature, 388: 626-627 (1997).
40. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Meth., 191: 131-142 (1996).
41. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J. Immunol. Meth., 203: 141-152 (1997).
42. + T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J. Infect. Dis., 178: 260-265 (1998).
43. Holtl, L., C. Rieser, C. Papesh, R. Ramoner, G. Bartsch, and M. Thurnher: CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet, 352:1358 (1998).
44. Hough, M. R., M. D. Reis, R. Singaraja, D. M. Bryce, S. Kamel-Reid, I. Dardick, M. L. Breitman, and I. A. Dube: A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 95:13853-13858 (1998).
45. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2:52-58 (1996).
46. Huang, A. Y. C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264:961-965 (1994).
47. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J. Exp. Med., 176:1693-1702 (1992).
48. Inaba, K., R. M. Steinman, M. W. Pack, H. Aya, M. Inaba, T. Sudo, S. Wolpe, and G. Schuler: Identification of proliferating dendritic cell precursors in mouse blood. J. Exp. Med., 175:1157-1167 (1992).
49. Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stocken, L. J. Old, and A. Knuth: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histo-compatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med., 187:265-270 (1998).
50. Jiang, W., W. J. Swiggard, C. Heufler, M. Peng, A. Mirza, R. M. Steinman, and M. C. Nussenzweig: The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature, 375:151-155 (1995).
51. Jonuleit, H., U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol., 27:3135-3142 (1997).
52. Kelsall, B. L. and W. Strober: Distinct populations of dendritic cells are present in the subepithelial dome and T-cell regions of the murine Peyer's patch. J. Exp. Med., 183:237-247 (1996).
53. Kleijmeer, M. J., M. A. Ossevoort, C. J. van Veen, J. J. van Hellemond, J. J. Neefjes, W. M. Kast, C. J. Melief, and H. J. Geuze: MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J. Immunol., 154:5715-5724 (1995).
54. Knight, S. C., R. Hunt, C. Dore, and P. B. Medawar: Influence of dendritic cells on tumor growth. Proc. Natl. Acad. Sci. U.S.A., 82:4495-4497 (1985).
55. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler: High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med., 184:741-746 (1996).
56. Kupiec-Weglinski, J. W., J. M. Austyn, and P. J. Morris: Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues. J. Exp. Med., 167:632-645 (1988).
57. Labeur, M. S., B. Roters, B. Pers, A. Mehling, T. A. Luger, T. Schwarz, and S. Grabbe: Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol., 162:168-175 (1999).
58. Levin, D., S. Constant, T. Pasqualini, R. Flavell, and K. Bottomly: Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. J. Immunol., 151:6742-6750 (1993).
59. Lindhout, E., C. G. Figdor, and G. J. Adema: Dendritic cells: migratory cells that are attractive. Cell Adhes. Commun., 6:117-123 (1998).
60. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med., 3:625-631 (1997).
61. Mackey, M. F., J. R. Gunn, C. Maliszewsky, H. Kikutani, R. J. Noelle, and R. J. Barth Jr.: Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol., 161:2094-2098 (1998).
62. Maldonado-López, R., T. De Smedt, P. Michel, J. Godfroid, B. Pajak, C. Heirman, K. Thielemans, O. Leo, J. Urbain, and M. Moser: CD8α+ and CD8α- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med., 189:587-592 (1999).
63. Manz, R., M. Assenmacher, E. Pfluger, S. Miltenyi, and A. Radbruch: Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc. Natl. Acad. Sci. U.S.A., 92: 1921-1925 (1995).
64. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med., 184:1953-1962 (1996).
65. Marakowsky, E., B. Pulendran, and K. Shortman: Lymphoid-related dendritic cells. In: Dendritic Cells (M. T. Lotze and A. W. Thomson, Eds.) Academic Press, San Diego, CA 92101-4495 (1999).
66. Marland, G., A. B. Bakker, G. J. Adema, and C. G. Figdor: Dendritic cells in immune response induction. Stem Cells, 14:501-507 (1996).
67. Marquez, C., C. Trigueros, E. Fernandez, and M. L. Toribio: The development of T and non-T-cell lineages from CD34+ human thymic precursors can be traced by the differential expression of CD44. J. Exp. Med., 181:475-483 (1995).
68. Matzinger, P.: Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12:991-1045, 1994.
69. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302 (1995).
70. Melief, C. J.: Dendritic cells as specialized antigen-presenting cells. Res. Immunol., 140: 902-906 (1989).
71. Menetrier-Caux, C, G. Montmain, M. C. Dieu, C. Bain, M. C. Favrot, C. Caux, and J. Y. Blay: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 92: 4778-4791 (1998).
72. Metlay, J. P., M. D. Witmer Pack, R. Agger, M. T. Crowley, D. Lawless, and R. M. Steinman: The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med., 171: 1753-1771 (1990).
73. Mintz, B. and W. K. Silvers: Transgenic mouse model of malignant skin melanoma. Proc. Natl. Acad. Sci. U.S.A., 90: 8817-8821 (1993).
74. Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly: Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res., 59: 56-58 (1999).
75. Morse, M. A., Y. Deng, D. Coleman, S. Hull, E. Kitrell-Fisher, S. Nair, J. Schlom, M. E. Ryback, and H. K. Lyerly: A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res., 5: 1331-1338 (1999).
76. Mortarini, R., A. Anichini, M. Dinicola, S. Siena, M. Bregni, F. Belli, A. Molla, A. M. Gianni, and G. Parmiani: Autologous dendritic cells derived from CD34(+) pro-genitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of Melan-A/ Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res., 57: 5534-5541 (1997).
77. Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380 (1996).
78. Murphy, G. P., B. A. Tjoa, S. J. Simmons, J. Jarisch, V. A. Bowes, H. Ragde, M. Rogers, A. Elgamal, G. M. Kenny, O. E. Cobb, R. C. Ireton, M. J. Troychak, M. L. Salgaller, and A. L. Boynton: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate, 38: 73-78 (1999).
79. Nair, S. K., D. Snyder, B. T. Rouse, and E. Gilboa: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer, 70: 706-715 (1997).
80. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332 (1998).
81. Okuyama, T., Y. Maehara, Y. Kakeji, S. Tsuijitani, D. Korenaga, and K. Sugimachi: Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer, 82: 1468-1475 (1998).
82. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med., 187: 693-702 (1998).
83. Ossevoort, M. A., M. C. Feltkamp, K. J. van Veen, C. J. Melief, and M. W. Kast: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. Emphasis Tumor Immunol., 18: 86-94 (1995).
84. Peron, J. M., C. Esche, V. M. Subbotin, C. Maliszewski, M. T. Lotze, and M. R. Shurin: FLT3-ligand administration inhibits liver metastases: role of NK cells. J. Immunol., 161: 6164-6170 (1998).
85. Porgador, A. and E. Gilboa: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med., 182: 255-260 (1995).
86. Pulendran, B., J. L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky, and C. R. Maliszewski: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. U.S.A., 96: 1036-1041 (1999).
87. Punt, C. J. A., J. de Vries, A. A. O. Eggert, N. Scharenborg, D. J. Ruiter, C. Britten, G. J. Adema, and C. G. Figdor: Immunization of melanoma patients with autologous dendritic cells pulsed with synthetic gp100 and tyrosinase peptides. Proc. A. A. C. R., 40: (1999).
88. Radmayr, C., G. Bock, A. Hobisch, H. Klocker, G. Bartsch, and M. Thurnher: Dendritic antigen-presenting cells from the peripheral blood of renal cell-carcinoma patients. Int. J. Cancer, 63: 627-632 (1995).
89. Randolph, G. J., S. Beaulieu, S. Lebecque, R. M. Steinman, and W. A. Muller: Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science, 282: 480-483 (1998).
90. Reddy, A., M. Sapp, M. Feldman, M. Subklewe, and N. Bhardwaj: A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood, 90: 3640-3646 (1997).
91. + T-helper and a T-killer cell. Nature, 393: 474-478 (1998).
92. Rissoan, M. C., V. Soumelis, N. Kadowaki, G. Grouard, F. Briere, R. de Waal Malefyt, and Y. J. Liu: Reciprocal control of T helper cell and dendritic cell differentiation. Science, 283: 1183-1186 (1999).
93. Romani, N. and G. Schuler: The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system. Springer Semin. Immunopathol., 13: 265-279 (1992).
94. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler: Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180:83-93 (1994).
95. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, and G. Schuler: Generation of mature dendritic cells from human blood: an improved method with regard to clinical applicability. J. Immunol. Meth., 196:137-151 (1996).
96. Rosenberg, S. A.: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18:175-182 (1997).
97. Salazar-Onfray, F., T. Nakazawa, V. Chhajlani, M. Petersson, K. Karre, G. Masucci, E. Celis, A. Sette, S. Southwood, E. Appella, and R. Kiessling: Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res., 57:4348-4355 (1997).
98. Sallusto, F. and A. Lanzavecchia: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179:1109-1118 (1994).
99. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med., 182:389-400 (1995).
100. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393:480-483 (1998).
101. Schreurs, M. W., A. A. Eggert, A. J. de Boer, C. G. Figdor, and G. J. Adema: Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur. J. Immunol., 29:2835-2841 (1999).
102. Shen, Z., G. Reznikoff, G. Dranoff, and K. L. Rock: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol., 158:2723-2730 (1997).
103. Shimizu, K., R. C. Fields, M. Giedlin, and J. J. Mule: Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. U.S.A., 96:2268-2273 (1999).
104. Smith, A. L. and B. F. de St Groth: Antigen-pulsed CDSalpha+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J. Exp. Med., 189:593-598 (1999).
105. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, S. A. Rosenberg, and P. Hwu: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med., 186:1213-1221 (1997).
106. Steinbrink, K., H. Jonuleit, G. Muller, G. Schuler, J. Knop, and A. H. Enk: Interleukin-10-treated human dendritic cells induce a melanoma-antigen- specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood, 93:1634-1642 (1999).
107. Steinman, R. M.: The dendritic cell system and its role in immunogenicity. Annu. R. Rev. Immunol., 9:271-296 (1991).
108. Steinman, R. M. and Z. A. Cohn: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med., 137:1142-1162 (1973).
109. Stene, M. A., M. Babajanians, S. Bhuta, and A. J. Cochran: Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. J. Invest. Dermatol., 91: 125-128 (1988).
110. Suss, G. and K. Shortman: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med., 183:1789-1796 (1996).
111. Te Velde, A. A., J. P. Klomp, B. A. Yard, J. E. de Vries, and C. G. Figdor: Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J. Immunol., 140:1548-1554 (1988).
112. Thurner, B., C. Roder, D. Dieckmann, M. Heuer, M. Kruse, A. Glaser, P. Keikavoussi, E. Kampgen, A. Bender, and G. Schuler: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Meth., 223:1-15 (1999).
113. Thurnher, M., C. Papesh, R. Ramoner, G. Gastl, G. Bock, C. Radmayr, H. Klocker, and G. Bartsch: In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp. Hematol., 25:232-237 (1997).
114. Thurnher, M., C. Radmayr, R. Ramoner, S. Ebner, G. Bock, H. Klocker, N. Romani, and G. Bartsch: Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer, 68:1-7 (1996).
115. Thurnher, M., C. Rieser, L. Holtl, C. Papesh, R. Ramoner, and G. Bartsch: Dendritic cell-based immunotherapy of renal cell carcinoma. Urol. Int., 61:67-71 (1998).
116. Tillman, B. W., T. D. de Gruijl, S. A. Luykx-de Bakker, R. J. Scheper, H. M. Pinedo, T. J. Curiel, W. R. Gerritsen, and D. T. Curiel: Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol., 162:6378-6783 (1999).
117. Toriyama, K., D. R. Wen, E. Paul, and A. J. Cochran: Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J. Invest. Dermatol., 100:2698-273S (1993).
118. Troy, A., P. Davidson, C. Atkinson, and D. Hart: Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol., 160:214-219 (1998).
119. Tsai, V., S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis: Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol., 158:1796-1802 (1997).
120. Tsujitani, S., T. Furukawa, R. Tamada, T. Okamura, K. Yasumoto, and K. Sugimachi: Langerhans cells and prognosis in patients with gastric carcinoma. Cancer, 59:501-505 (1987).
121. Turing, T., A. B. DeLeo, M. T. Lotze, and W. J. Storkus: Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol., 27:2702-2707 (1997).
122. Vremec, D. and K. Shortman: Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J. Immunol., 159:565-573 (1997).
123. Wang, J., S. Saffold, X. Cao, J. Krauss, and W. Chen: Eliciting T-cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol., 161:5516-5524 (1998).
124. Zhou, L. J. and T. F. Tedder: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. U.S.A., 93:2588-2592 (1996).
125. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. Deleo, M. R. Clarke, M. T. Lotze, and W. J. Storkus: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183:87-97 (1996).
126. Zitvogel, L., A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi Castagnoli, G. Raposo, and S. Amigorena: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med., 4:594-600 (1998).